Overview

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection

Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Interventional, single arm, single-centre trial to evaluate the effectiveness and safety of fecal microbiota therapy (FMT) in the investigators population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Queen Elizabeth II Health Sciences Centre
Treatments:
Antidiarrheals
Loperamide
Metronidazole
Vancomycin